FORGOTTEN HISTORY: Regeneron - Caught on Camera

Experimental Regeneron Antibody Trevogrumab Cut Lean Mass Loss by About 42% in Semaglutide Users Over One Year

In a company-funded Phase 2 trial, Regeneron's experimental trevogrumab cut lean mass loss by about 42% at the 75 mg dose in semaglutide users over a year.

Medical Daily · Oct 3

An $8 Billion Reason Why Regeneron Stock Is in Focus

Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.

Barchart · Oct 2

Why Citi Is Sounding the Alarm on Moderna Stock

The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.

Barchart · Oct 1

Where the Body Parks Its Fat May Matter More Than How Much, and One Gene Splits by Sex

A million-person study measured where fat sits, not just how much. Among 59 genes, one showed a notably stronger effect in women than in men.

Medical Daily · Aug 19

This 16-year-old Canadian student built an autonomous AI-powered robot turtle that can detect tiny microplastics in water

This 16-year-old built an autonomous AI-powered robot turtle that detects microplastics in water. The Canadian student created the turtle-inspired robot to scan water for tiny plastic particles using 3D holographic imaging and artificial intelligence. The innovative system can detect microplastics with high accuracy and won a major award and scholarship…

The Economic Times · Aug 18

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint…

The Economic Times · Aug 17

Meet Connor Hill, the 17-year-old Pennsylvania student who wrote a computer program to classify noble polyhedra; he proved there are 146 isolated examples and won $250,000

Connor Hill triumphed in the competition with his exceptional algorithm for classifying noble polyhedra, discovering two infinite families alongside 146 distinct shapes. Edward Kang's AI tool for autism screening claimed the second position, and Iris Shen's innovative blood cancer research involving clams took third place. Additionally, Regeneron expressed their commitment…

The Times of India · Aug 16

About 1 in 7,000 People Carry a Broken Gene That Appears to Keep Them Lean, and Drugmakers Noticed

A Nature study of more than 1 million people found rare FNIP1 variants associated withFNIP1 gene, metabolic health genetics, liver fat, TG:HDL ratio, cardiometabolic disease, Regeneron Genetics Center, obesity genetics less liver fat, lower blood sugar, and 60% lower odds of disease.

Medical Daily · Aug 12

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is set to report its second-quarter results this month, with analysts expecting a double-digit decline in earnings year over year.

Barchart · Jul 23

What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in Congo

A rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. While potentially less lethal than other Ebola strains, its high mortality rate necessitates basic public health measures. Promising vaccine and therapy candidates are undergoing clinical trials.

The Economic Times · May 29